Lifeboat Foundation

Developed in Spain, the Arca system integrates solar panels, power electronics, and energy storage. Arca Lite has a rated power of 490 Wp, and Arca Plus of 980 Wp.

From pv magazine Latam

The Spanish companies Solartia and IED — experts in energy and electronics, respectively — have launched Arca, an autonomous solar power generator described as a robust and low-maintenance system that aims to alleviate energy poverty.

Continue reading “Solar-plus-storage autonomous power generator from Spain” »

Academics say the material could be used to create unclonable physical components suitable for supporting digital security.

There is nothing inevitable about aging, or about its rate. Californian bristlecone pines are believed to live for 5,000 years, and there are long-lived mammalian creatures as well. Some marine creatures do not display any signs of aging at all, including hydra, jellyfish, planarian worms, and coral. Certain human cells have immortal characteristics too. When a woman gives birth, she produces a baby which is “new”. Her “germline” (reproduction-related) cells produce a child with no signs of age.

These and many other considerations combine with the unreasonable effectiveness of modern AI to lead some people to believe that significant advances in longevity are imminent. These advances probably cannot happen without the active participation of the wider pharmaceutical industry, and the acceptance by policy makers and regulators that aging is a disease, not just an unfortunate and inevitable component of the human condition. There is still considerable reluctance among major pharmaceutical companies to contemplate specific anti-aging therapeutic developments. But there are encouraging signs of this reluctance being challenged, especially at Novartis and AstraZeneca.

Beyond the pharma giants, Mellon reckons there are 255 companies which claim to be specifically targeting aging, of which 35 are listed on stock markets. But he thinks that only a minority of them are genuinely working to tackle aging, as opposed to one of the diseases it causes, like cancer, dementia, or heart disease. He likens the state of the longevity industry today to the internet industry of 20 years ago, when it was still in its dial-up phase, and downloading information (or, heaven forbid, images) was like sucking jelly through a straw. And although longevity will have such a massive impact on all of us that you might expect progress to be expedited, Mellon points out that the internet did not have to go through lengthy and expensive FDA trials at every step.

Autophagy is often likened to the trash management system of the cell. And just as municipal waste services involve collection, transportation and ultimately disposal, so too must the cell’s autophagy system follow a coordinated, multistep process. It first requires cellular refuse to be bagged up inside sack-like structures known as phagophores. These then mature into cargo containers called autophagosomes, which fuse with degradation hubs called lysosomes. Only then do waste products get broken down.

Any part of that cell-cleaning process could go wrong, and they often do as cells age. But if researchers do not fully understand what aspects of autophagy are defective in any particular disease, drugs that modulate the wrong parts of the pathway could do more harm than good. A therapy could, for instance, help the cell to package more trash. “But if your trash compactor isn’t working properly, you’re just going to end up with a room full of trash bags,” says Tim Sargeant, who studies autophagy at the South Australian Health and Medical Research Institute in Adelaide. “That’s one of the dangers here.”

As a result, although some anti-ageing researchers and companies have gone all-in on targeting autophagy, others are more circumspect — especially given the lack of solid evidence in people or even mouse models for many of the proposed interventions.

Cardiovascular disease is the leading cause of death worldwide and bears an immense economic burden. Late-stage heart failure often requires total heart transplantation; however, due to donor shortages and lifelong immunosuppression, alternative cardiac regenerative therapies are in high demand. Human pluripotent stem cells (hPSCs), including human embryonic and induced pluripotent stem cells, have emerged as a viable source of human cardiomyocytes for transplantation. Recent developments in several mammalian models of cardiac injury have provided strong evidence of the therapeutic potential of hPSC-derived cardiomyocytes (hPSC-CM), showing their ability to electromechanically integrate with host cardiac tissue and promote functional recovery. In this review, we will discuss recent developments in hPSC-CM differentiation and transplantation strategies for delivery to the heart. We will highlight the mechanisms through which hPSC-CMs contribute to heart repair, review major challenges in successful transplantation of hPSC-CMs, and present solutions that are being explored to address these limitations. We end with a discussion of the clinical use of hPSC-CMs, including hurdles to clinical translation, current clinical trials, and future perspectives on hPSC-CM transplantation.

Cardiovascular disease (CVD) is the leading cause of death worldwide. In the United States alone, CVD is responsible for ~655,000 deaths and contributes to $200 billion in spending each year. CVD can lead to myocardial infarction (MI), also known as a “heart attack,” which results in restricted blood flow and extensive cell death within the infarct zone. Due to the limited regenerative capacity of the human heart, infarcted myocardium is replaced by fibrotic scar tissue with inferior contractile performance. Over time, pathological remodeling leads to ventricular wall thinning, which can progress to heart failure. There is currently no treatment available that can restore lost cardiomyocytes after MI, and conventional therapies typically only manage the symptoms (3, 4).

The encrypted chats detect when you take a screenshot.

After several years of development, Facebook’s Messenger platform will let you switch to end-to-end encrypted chats and calls with anyone. It also now supports features like Reactions and replies inside encrypted chats.

Three separate teams worldwide published the feat on Nature — all on the same day.

In a historic milestone for silicon-based quantum computing systems, three separate teams of researchers have published papers on Nature, detailing the steps and system architecture required for fault-tolerant quantum computing.

Lister says during this talent shortage, companies are going to need to meet the demands of workers, which will likely include a hybrid model.

Her research found that 56% of U.S. workers have a job that can be done at least partially remotely. She says allowing employees to shift their hours, which days they work, and even when they take a break can have a huge impact on retention.

Technology will have an outsized role in how companies implement their hybrid models. Lister says that within five years, employees may be able to meet via hologram instead of through a video call.

Frogs briefly treated with a five-drug cocktail administered by a wearable bioreactor on the stump were able to regrow a functional, nearly complete limb.

For millions of patients who have lost limbs for reasons ranging from diabetes to trauma, the possibility of regaining function through natural regeneration remains out of reach. Regrowth of legs and arms remains the province of salamanders and superheroes.

But in a study published in the journal Science Advances, scientists at Tufts University and Harvard University’s Wyss Institute have brought us a step closer to the goal of regenerative medicine.